Oxford Biomedica
Organization
Oxford Biomedica (OXB) is a leading gene and cell therapy company specializing in the development and manufacturing of gene-based medicines. Operating as a contract development and manufacturing organization (CDMO), it provides critical viral vector solutions to power progressive cell and gene therapies globally.
What experts have said about Oxford Biomedica
5 statements · 5 negative
Oxford Biomedica cut its full-year revenue and profitability guidance.
“they cut their full year revenue and profitability guidance.”
Open the episode · Frasers Group Up, Royal Unibrew Drops, OXB DownListen at 4:05
Oxford Biomedica is loss-making and consuming cash, complicating valuation.
“It's loss-making and cash-burning, so it's quite a leap of faith here to actually value it.”
Open the episode · Paul's Podcast - Fri 7 Aug 2026Listen at 14:59
Oxford Biomedica is currently far below its revenue target.
“it's nowhere near that level at the moment.”
Open the episode · Paul's Podcast - Fri 7 Aug 2026Listen at 15:32
Paul would not personally invest in Oxford Biomedica.
“So it's not the sort of thing I would personally invest in.”
Open the episode · Paul's Podcast - Fri 7 Aug 2026Listen at 15:44
Paul Scott would not personally invest in Oxford Biomedica.
“It's not the sort of thing I would personally invest in.”
Open the episode · Paul's Podcast - Fri 7 Aug 2026Listen at 15:45
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
2 episodes featuring Oxford Biomedica
Stock Movers
Frasers Group nears control of Hugo Boss as rivals stumble
The episode tracks three distinct market signals: a near-controlling stake in Hugo Boss, weak Royal Unibrew earnings, and a downgrade-driven fall for Oxford Biomedica.
Aug 18, 2026 · 7 min
UK Small/Mid Caps with Paul Scott
Paul Scott opens a delayed small-cap market discussion
The episode offers a brief window into the format and participants behind a UK small- and mid-cap investing podcast.
Aug 7, 2026 · 27 min